

Icahn Institute: Stay connected with us!



@multiscalebio

Mining the digital universe of data to develop
personalized cancer therapies

August 12, 2013



Icahn School of Medicine at
Mount Sinai



Disclosures

- I am on the Scientific Advisory Board for
 - Pacific Biosciences
 - Numedii
 - StationX
 - Spiral Genetics
 - Berg Pharmaceuticals
 - Ingenuity
 - GNS Healthcare
- I am on the Board of Directors for
 - Sage Bionetworks
 - While Biome

Disclosures



- Given the apparent rampant use of performance enhancing drugs in sports:

MOLECULAR STRUCTURE OF STEROIDS...



Poll results: look who's doping

In January, *Nature* launched an informal survey into readers' use of cognition-enhancing drugs. **Brendan Maher** has waded through the results and found large-scale use and a mix of attitudes towards the drugs.




I fall on the “never used” curve

20% are abusing

- I used no performance enhancing drugs to carry out any of the research I will discuss today

Considering the digital universe of data to better diagnose and treat patients



We need to be able to leverage the digital universe of information to best solve the most challenging problems


1.8

ZETTABYTES

(1.8 trillion gigabytes of information will be created and replicated in 2011; growth continues to accelerate – factor of 9 growth in last 5 years)

Being masters of really big data now critical for biomedical research (TB → PB → EB → ZB)

Cost per Raw Megabase of DNA Sequence




Organisms

Tissues

Single cells


Single cell,
real-time,
continuous?

Big Data Warehouses at Medical Centers like Mount Sinai Contain Virtually All Facts And Transaction Records For Millions of Patients




Institute for Personalized Medicine at Mount Sinai

Multiscale measures of patients now available through efforts like Mount Sinai's Biobank (>25,000 *identified* patients and growing fast)




These technologies are enabling scoring of very large-scale, high-dimensional data on individuals for low cost




- Modified and unmodified DNA
- Modified and unmodified coding and non-coding RNA
- Phosphorylated and unphosphorylated proteins
- Metabolites

That promise to enable the construction of molecular networks that define the biological processes that comprise living systems



Integrating data to build predictive models of living systems
(■ - DNA, ■ - RNA, ■ - Protein, ■ - Metabolite)




Mendelian Randomization as a Path to Causal Inference


Cytogenet Genome Res 105:363–374 (2004)
DOI: 10.1159/000078209

An integrative genomics approach to the reconstruction of gene networks in segregating populations


J. Zhu,^a P.Y. Lum,^a J. Lamb,^a D. GuhaThakurta,^a S.W. Edwards,^a
R. Thieringer,^b J.P. Berger,^c M.S. Wu,^d J. Thompson,^e A.B. Sachs,^a and
E.E. Schadt^a




Leveraging DNA variations as a perturbation source is key to inferring causality




Understanding the network architecture critical for understanding how information flows through it



Stratifying patient populations






Organizing 163 genetic loci for IBD





Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease




Problem: How do you make sense of 163 loci to understand a complex disease like IBD?

The Omental Adipose Network









Connections between diseases and tissues: IBD network driving Alzheimer's


Building networks from 500 prefrontal cortex samples




Constructing the co-expression networks



“Normal” versus LOAD Networks




Systems analysis of eleven rodent disease models reveals an inflammatome signature and key drivers




Similar set: upregulated	Enrichment P	Overlap	Set
Inflammatory response	$4.76\text{E} - 61$	208	704
Leukocyte activation	$2.13\text{E} - 32$	164	704
Regulation of immune response	$1.44\text{E} - 25$	84	260
Cytokine production	$6.10\text{E} - 18$	85	335
Chemotaxis	$4.97\text{E} - 16$	74	284
Humoral immune response	$3.25\text{E} - 14$	69	271
Mitotic cell cycle	$7.64\text{E} - 13$	87	414
Induction of apoptosis	$1.74\text{E} - 12$	86	412
TLR signaling pathway	$4.66\text{E} - 12$	21	47
Phagocytosis	$2.74\text{E} - 11$	38	111
Innate immune response	$9.29\text{E} - 11$	48	173
ECM remodeling	$9.67\text{E} - 11$	22	59
Osteoclast differentiation	$3.61\text{E} - 10$	31	82
Regulation of cell proliferation	$4.19\text{E} - 10$	112	662
Antigen processing and presentation	$7.44\text{E} - 10$	32	89
Positive regulation of translation	$3.64\text{E} - 09$	45	170
Cytokine production by Th17 cells	$6.33\text{E} - 09$	17	40
Angiogenesis	$9.41\text{E} - 09$	60	277
Cell-cycle process	$2.79\text{E} - 08$	104	636
Wound healing	$1.79\text{E} - 07$	57	274
Regulation of translation	$4.44\text{E} - 07$	66	349
Macrophage activation	$1.61\text{E} - 06$	20	49
Interleukin-12 production	$1.70\text{E} - 06$	18	40

Core disease modules harbor pluripotent drug targets




Functional chemigenomics screen: Chemical perturbagens against disease networks *in silico*




Topiramate Reduces IBD Severity in a TNBS Rodent Model of IBD

- TNBS chemically induced rat model of IBD
- Animals treated with 80mg/kg topiramate oral after sensitization
- Prednisolone positive control (approved for IBD in humans)




Leveraging NGS and Predictive Network Models to Drive Personalized Cancer Therapy




chr17 in tumor S1 underwent somatic copy number loss

LOH of the whole chromosome 17, which includes
TP53, BRCA1, CDK12, ERBB2, TRIM37


17p has an one copy loss in 77% Ovarian cancer samples in TCGA




Frameshift deletion A411fs found in CDK12 in both sites



CDK12 primes HOW/Crn-dependent splicing in fly glial cells



CDK12 mutation results in loss of kinase domain



Normal: aa401 RKKKERAAAAAAAAAKMDGKESKGSPVFLPRKENSSVEAKDS...

Mutant: aa401 RKKKERAAAAA**KQRWMERSPRVHLYFCLEKRTVQ***

NLS: nuclear localization signal

RS domain: arginine/serine-rich domain


PEST region: peptide sequence rich in proline

kinase domain: serine-threonine kinase domain


PRM: proline-rich motif

Ko TK (J Cell Sci 2001)
Chen HH (Mol Cell Biol 2006)
Tagliatela A (PhD thesis 2012)


Personalized multiscale tumor networks to diagnose and treat cancers



Key driver analysis: Identifying those genes that regulate network states that have larger impact on outcomes




Patient mutation data projected onto the network: Interesting 1000-node subnetwork identified




- Full network comprised of 7,881 expr/2,331 CNV nodes, 306 regulators, 501 functional mutations
- Subnetwork: 116 regulators, 232 functional mutations – massive enrichment ($p = 4.5e-173$)
- 6 mutations affecting master regulators in patient and TCGA data, including ASPM and CENPF related to BUB1B dependency
- Many pathways dramatically enriched: transmembrane receptor protein tyrosine kinase activity, collagen binding, axonogenesis and so on



Using multiscale tumor networks to inform personalized chemotherapy options



Aiming to build personalized multiscale networks to model dynamics of complex disease




High-dimensional data acquisition carried out over time and at multiple scales can provide for the precision medicine approach we all seek



Ultimate Objective: Predictive models to navigate your health course throughout the course of your life

Normal State



Adapted from Rui Chang et al. *PLoS Computational Biology*

Acknowledgements

Mount Sinai	PacBio	Cornell	CSHL
Ali Bashir Bobby Sebra Joel Dudley Andrew Kasarskis Milind Mahajan Gintaras Deikus Jun Zhu Bin Zhang Michael Linderman Gaurav Pandey Bojan Losic Omar Jabado Glenn Farrell	Jason Chin Yan Gao Greg Khitrov Frank Boellmann Ellen Paxinos David Rank Paul Peluso Edwin Hauw	Chris Mason Roger Altman Russell Durrett	Richard McCombie Eric Antoniou Patricia Mocombe
New York Genome Center	Sage Bionetworks		
Bob Darnell	Stephen Friend Chris Gaiteri		



Stay connected with us!
[@multiscalebio](https://twitter.com/multiscalebio)